KleinRMoghadam-KiaSTaylorL, et al.Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol2011; 64: 849–858.
3.
KuhnAAbererEBata-CsörgőZ, et al.S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol2017; 31: 389–404.
4.
FanouriakisAKostopoulouMAlunnoA, et al.2019update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78: 736–745.
5.
FurieRAMorandEFBruceIN, et al.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. The Lancet Rheumatology2019; 1: e208–e219.
6.
MorandEFFurieRTanakaY, et al.Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med2020; 382: 211–221.
7.
PlüßMPiantoniSWincupC, et al. Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab – A case-based review of clinical trial data suggesting A domain-based therapeutic approach. J Clin Med. 2022; 11(12): 3449. doi:10.3390/jcm11123449
8.
KalunianKCFurieRMorandEF, et al.A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol2023; 75: 253–265.
9.
PetriMOrbaiA-MAlarcónGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
10.
KleinRMoghadam-KiaSLoMonicoJ, et al.Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus. Arch Dermatol2011; 147: 203–208.
11.
BlumFRSampathAJFoulkeGT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol2022; 47: 1998–2001.
